ANI Pharmaceuticals (ANIP) experienced a significant drop of 7.78% in pre-market trading on Friday, despite reporting strong third-quarter results and raising its full-year guidance. The pharmaceutical company's stock movement contradicts its positive financial performance, leaving investors puzzled.

ANI Pharmaceuticals announced record third-quarter results for 2025, with adjusted earnings per share of $2.04, surpassing the analyst consensus estimate of $1.75. The company's revenue for the quarter reached $227.8 million, beating expectations of $211 million. Additionally, ANI reported a net income of $26.3 million and adjusted EBITDA of $59.6 million for the quarter.

In light of these strong results, ANI Pharmaceuticals raised its full-year 2025 guidance. The company now expects revenue between $854 million and $873 million, up from its previous range of $818 million to $843 million. Adjusted earnings per share for the year are projected to be in the range of $7.37 to $7.64, an increase from the prior guidance of $6.98 to $7.35. Despite these positive developments, the stock's sharp decline suggests that other factors may be influencing investor sentiment, potentially related to broader market conditions or specific industry concerns not immediately apparent from the reported results.